Phibro Animal Health Corp (PAHC) Stock — Forensic Analysis, Red Flags & Rating | Stockonomy · Stockonomy
Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Aug 11, 2026
Phibro Animal Health Corp (PAHC)
A forensic read on Phibro Animal Health Corp built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
C · Mixed — selective
Forensic grade
Safe
Financial health
5.1
Distress distance
Clean
Earnings quality
4
Forensic signals
15.1
P / E (ttm)
16.9%
ROE
$1.4B
Market cap
1.35%
Dividend yield
27.4%
Revenue growth
This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.
Phibro Animal Health Corp earns a C (Mixed — selective) forensic quality grade, and its balance-sheet distress test reads 5.1, placing it in the Safe zone. 4 forensic signals were flagged in its latest SEC filings, led by accruals ratio (% of noa).
What the filings flag
+61.7%
FY2024→FY2025
Accruals ratio (% of NOA).Net operating assets grew +61.7% relative to their own average in FY2025 — scaled by NOA itself, not total assets (see the Forensic Screens card's differently-scaled Sloan Accrual Ratio for that read). Accruals are building sharply — a large slice of profit sits in operating assets, not cash; Richardson/Sloan link high accruals to weaker future returns as they reverse. The build is led by inventory up +67% against +27% in cost of sales and receivables up +35% against revenue +27%. The cash-flow cross-check is more mixed: reported earnings ran in line with operating cash by 4% of net operating assets, diverging from the balance-sheet accrual read.
7.8%
FY2025
Return on invested capital.Return on invested capital is 7.8% in the latest fiscal year and steady — slightly below its ~10% cost of capital — reinvestment is roughly a wash.
+0.1%/yr
FY2022–FY2025
Share count.Diluted share count changed +0% over the last 3 years to FY2025 (+0.1%/yr). Roughly flat — the count is neither shrinking nor growing meaningfully. Per-share value isn't being meaningfully helped or hurt by the count.
-38%
FY2014→FY2015
Dividend — cut.The payout was CUT ~38% in FY2015 (from FY2014) and hasn't been restored since. It still returns some cash, but it is NOT the dependable, rising dividend an unbroken streak implies. Measured on total dividend dollars rather than per share: the reported share count steps sharply around FY2014, a stock-split seam between filing vintages rather than a change in the payout, and a split leaves the dollars paid untouched.
Key fundamentals
Latest Revenue$1.30B
Revenue Growth YoY+27.4%
Revenue CAGR (3yr)+11.2%
Net Margin3.7%
Free Cash Flow$41.8M
Return on Equity16.9%
Debt / Equity2.64x
The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Phibro Animal Health Corp's actual 10-K/10-Q/8-K filings?